Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [scRNA-seq]

ABSTRACT: Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [scRNA-seq]

PROVIDER: PRJNA984274 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24946621_1.fastq.gz	Fastqsanger.gz
	SRR24946621_2.fastq.gz	Fastqsanger.gz
	SRR24946623_1.fastq.gz	Fastqsanger.gz
	SRR24946623_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells

Project description:Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells

| PRJNA984281 | ENA

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [9a]

Project description:Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [9a]

| PRJNA984289 | ENA

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [cycling and quiescent fractions]

Project description:Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [cycling and quiescent fractions]

| PRJNA984288 | ENA

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [shCTL vs shNCOA4]

Project description:Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [shCTL vs shNCOA4]

| PRJNA984273 | ENA

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [9a]

Project description:Acute myeloid leukemia (AML) remains a challenging hematological malignancy with poor prognosis and limited treatment options. Post-therapy relapse, particularly driven by leukemic stem cells (LSCs), contributes to therapeutic failure and adverse outcome. Here, we investigated the role of quiescence and its associated molecular mechanisms in AML pathogenesis and identified potential vulnerabilities for therapeutic intervention. We found that quiescent AML cells, enriched for LSC functions, exhibited a distinct gene set that served as a significant prognostic factor for poor outcomes in AML patients. Furthermore, quiescent cells displayed heightened autophagic activity, with a reliance on ferritinophagy, a selective form of autophagy mediated by Nuclear Receptor Coactivator 4 (NCOA4), for iron bioavailability. Inhibition of NCOA4 genetically or chemically showed potent anti-leukemic effects, particularly targeting the LSC compartment. These findings uncover that ferritinophagy inhibition may represent a promising therapeutic strategy for patients with AML.

2024-06-16 | GSE235069 | GEO

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [cycling and quiescent fractions]

2024-06-16 | GSE235060 | GEO

Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells [scRNA-seq]

2024-06-16 | GSE235058 | GEO